U.S. is Most Attractive Country for Biopharma Investment

In a new study from Pugatch Consilium consultancy, the U.S. and European economies continue to top the global charts in terms of attractiveness for biopharmaceutical investment. Notwithstanding low costs and considerable potential, emerging markets still come in at the bottom. Canada is also found to be surprisingly low on the list compared to developed economies, mainly due to challenging intellectual property policies.

The study, “Measuring the Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey (commissioned by PhRMA),” finds that economies with policy environments that support investment and innovation rank as the most attractive in the eyes of top level executives operating on the ground, while economies with weak biopharmaceutical policies are considered to be much less competitive.

“The study reaffirms that the policy environment matters,” said John Castellani, president and chief executive officer, PhRMA. “It shows that economies could be much better equipped to attract a portion of the billions of dollars invested globally by the biopharmaceutical industry each year if policy conditions improve and become more supportive.”